drugset
drugset / Trial / NCT03481920

A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

NCT03481920 ↗

Phase 0 Terminated 7 enrolled PH Research, S.L.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacodynamics, safety and efficacy of PEGPH20 in combination with Avelumab in adult patients with chemotherapy resistant advanced or locally advanced pancreatic ductal adenocarcinoma (PDAC). This is a multi-center, open-label, non-randomized trial.

Timeline

Start
2018-01-10
Primary completion
2019-01-10
Completion
2019-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Avelumab Monoclonal antibody 10 mg/kg Intravenous
Subject Pegvorhyaluronidase Alfa Protein / enzyme biologic 3 ug/kg Intravenous

Indications

pancreatic ductal adenocarcinoma